Amgen’s multiple myeloma treatment and AbbVie’s leukaemia drug among new medicines given the nod in Scotland
News
Teva gets FDA approval for easier-to-use inhaler
QVAR RediHaler aims to eliminate need for hand-breath coordination
NICE backs new treatment option for psoriasis
The National Institute for Health and Care Excellence has issued draft guidelines backing NHS use of Almirall’s Skilarence to treat moderate to severe plaque psoriasis.
Lilly’s novel migraine drug hits PhIII targets
Eli Lilly’s investigational, oral, first-in-class molecule lasmiditan has hit key targets a late-stage trial assessing its safety and efficacy as a treatment for acute migraine, raising hopes for a new approach to managing the condition.
FDA rejects second Vernalis cough/cold treatment
The US Food and Drug Administration has rejected Vernalis’ cough cold treatment CCP-08, which is being developed by US partner Tris Pharma.
NHS England launches trial to assess PrEP
NHS England has kicked off what it claims to be the world’s largest single trial assessing the full impact of a scheme that gives patients at high risk of contracting HIV drugs to prevent infection.
NICE leans towards a ‘no’ for Keytruda in urothelial cancer
Cost regulators for NHS therapies in England and Wales have turned down MSD’s immunotherapy Keytruda as a treatment for locally advanced or metastatic urothelial cancer.
Pancreatic cancer patients in England get CDF access to Abraxane
Patients with pancreatic cancer living in England can from today potentially get access to a new treatment option after funding for Celgene’s Abraxane was approved for NHS use.
Shire mulls over separation of neuroscience unit
Shire is considering cleaving its neuroscience division into a separate, publicly-listed entity in a move that would afford the firm a sharper focus on rare diseases.
AbbVie’s pan-genotypic hep C therapy cleared in the US
AbbVie’s hepatitis C therapy Mavyret has picked up an approval in the US just days after having been green lighted by regulators in Europe.
Communications Team of the Year: International challenge full, limited availability left for NHS – book your space now!
Communications Team of the Year 2017 is shaping up to be an exciting competition – the International Challenge is now FULL ahead of the 1 September deadline, with limited space avaialable in the NHS challenge – agencies are advised to submit their entry today to avoid missing out.
NICE invites Roche to submit Tecentriq for CDF
Roche’s Tecentriq has been rejected by NICE as a ‘routine’ treatment for advanced bladder cancer, but the drugmaker has been asked to submit a proposal for the immunotherapy’s inclusion within the Cancer Drugs Fund for a certain patient population.
MRC links with UCB in antibody initiative
The Medical Research Council and UCB have launched a new scheme designed to help accelerate work on the development of antibody-based therapeutics.
Janssen’s Plivensia given thumbs down by US advisors
US regulatory advisors are not recommending approval of Johnson & Johnson’s Plivensia for rheumatoid arthritis, having concluded – based on the data available – that the benefits of the drug do not outweigh the potential risks.
Wide range of companies set to be represented at Marketer & Comms Team of the Year 2017
This year’s competition has attracted entries from a wide range of companies, including Celgene, Shire, Bayer, AbbVie, Eisai Europe, Novartis, MSD, Lundbeck, Novo Nordisk, Internis, Sanofi, HFA Healthcare Products, Sandoz and Bristol-Myers Squibb Pharmaceuticals among others. “Don’t miss out on this crucial opportunity to identify and benchmark talent within your organisation and against others in the industry,” says PharmaTimes business manager and competition lead, Luci Chalk.
